Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Binoy Yohannan
Institutions:
University of Minnesota,
Mayo Clinic
Observed institutions:
University of Minnesota,
Mayo Clinic,
The University of Texas MD Anderson Cancer Center,
The University of Texas Health Science Center at Houston
OpenAlex ID:
A5032489227
Bispecific antibody targets and therapies in multiple myeloma
2024
·
Matthew Rees
, Nadine Abdallah
, et al.
·
Frontiers in Immunology
·
14
PDF
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival
2025
·
Matthew J. Rees
, Nadia Toumeh
, et al.
·
Amyloid
·
9
PDF
Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin
2022
·
Binoy Yohannan
, Adan Rios
, et al.
·
Journal of Hematology
·
4
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma
2026
·
Binoy Yohannan
, Benjamin W. Langworthy
, et al.
·
Blood Cancer Journal
·
1
PDF
A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era
2025
·
Jahanzaib Khwaja
, Amy Kirkwood
, et al.
·
Blood
·
1
Synchronous Diagnosis of Squamous Cell Carcinoma of the Lung and Mixed Cellularity Hodgkin Lymphoma of the Nasopharynx
2022
·
Binoy Yohannan
, Arthi Sridhar
, et al.
·
Cureus
·
1
PDF
Short-term financial toxicity in CAR T-cell therapy.
2026
·
Nidhi Umesh Desai
, Qing Cao
, et al.
·
Journal of Clinical Oncology
Predictors of renal response in AL amyloidosis following anti‐plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype
2026
·
Matthew J. Rees
, Binoy Yohannan
, et al.
·
British Journal of Haematology
Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
2024
·
Binoy Yohannan
, Angela Dispenzieri
, et al.
·
Blood
Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
2024
·
Binoy Yohannan
, Matthew James Rees
, et al.
·
Blood
Burkitt's Lymphoma Responding to Rituximab-Cyclophosphamide-Vincristine-Dexamethasone-Lenalidomide: Time for a Paradigm Shift?
2024
·
Adan Rios
, Kok Hoe Chan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
ABCL-692 Burkitt's Lymphoma Responding to Rituximab-Cyclophosphamide-Vincristine-Dexamethasone-Lenalidomide: Time for a Paradigm Shift?
2024
·
Adan Rios
, Kok Hoe Chan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
12
Citation count:
30
H-index:
3
I10-index:
1
Year
Topic
Type
